NEW YORK CITY, NY / ACCESS Newswire / May 5, 2026 / AI Maverick Intel, Inc. (“AIMV” or the “Company”) is providing an update on the continued commercial progress of HEAL Access Canada Inc. (together with its subsidiaries, “HEAL Access” or “HAC”), in connection with AIMV’s previously announced non-binding letter of intent (“LOI”) to acquire 100% of HAC.
Based on information provided to the Company by HEAL Access, the platform has reached a level of commercial deployment that AIMV believes reflects early-stage scale, with more than 10 live customer implementations and 13 signed enterprise agreements, including multiple agreements with affiliated entities within the HEAL Group ecosystem.
HEAL Access’ platform currently supports approximately 79 clinicians and over 118,000 connected patients across a growing range of deployments, including primary care, mental health, orthotics, chronic disease management, and payments-enabled wellness ecosystems in Canada, the United Kingdom, and the United States.
The platform is powered by HEALix, a proprietary agentic AI core developed by HEAL Access, which functions as an intelligence engine delivering personalized insights, automating complex workflows, and providing continuous, 24/7 health assistance designed to drive patient and clinician engagement. HEALix is designed to unify clinical records, patient engagement, and intelligent case management within a privacy-first framework aligned with HIPAA, PHIPA, PIPEDA, and GDPR. As platform adoption expands, AIMV believes HEALix has the potential to generate a growing longitudinal dataset across patients, providers, and care pathways, which may enhance the platform’s ability to deliver increasingly personalized and data-driven outcomes over time.
Positioning Within AIMV’s Strategy
As previously disclosed, AIMV has entered into an LOI with HEAL Group Holdings Inc. to acquire HAC as the initial transaction under its broader Right of First Refusal (“ROFR”) framework.
From AIMV’s perspective, the current level of commercial activity supports the strategic rationale for the proposed acquisition, including:
-
Establishing an immediate operating platform within the HEAL ecosystem
-
Gaining exposure to a rapidly scaling, data-centric healthcare infrastructure
-
Creating a foundation for a structured acquisition pipeline across HEAL’s portfolio
Importantly, the diversity of HEAL Access’ deployments spanning clinical care, enterprise wellness, payments infrastructure, and specialty services suggests a platform architecture capable of supporting multiple revenue streams and stakeholder groups within a unified ecosystem.
CEO Commentary
“The pace and breadth of commercial adoption we are seeing reinforces our conviction that HEAL Access is evolving into a meaningful operating platform, not just a technology concept,” said Wayne Cockburn, Chief Executive Officer of AIMV.
“What is particularly notable is the cross-functional nature of the deployments. This is not a single-use application, but a platform being adopted across multiple segments of the healthcare ecosystem. In our view, that significantly expands the long-term strategic and economic potential.
“As we advance toward a definitive agreement, we are increasingly focused on how HEAL Access can serve as a foundational asset within AIMV both as a standalone operating business and as a gateway to a broader pipeline of AI-enabled healthcare acquisitions under the ROFR framework.”
Commercial Footprint and Expansion
HEAL Access’ current deployments include organizations operating across mental health services, multi-clinic care networks, orthotics, and payments-enabled wellness platforms. Signed agreements extend into adjacent verticals, including specialty pharmacy, secure clinical communications, revenue-cycle management, and integrated wellness programs.
This expanding footprint reflects a hybrid SaaS model combining recurring subscription revenue with enterprise-level contracts and supports continued scaling across both clinical and institutional channels.
Next Steps
AIMV and HEAL Group continue to work in good faith toward the negotiation and execution of a definitive agreement. The proposed transaction remains subject to customary conditions, including completion of due diligence, negotiation of final terms, and receipt of all required regulatory and shareholder approvals.
There can be no assurance that a definitive agreement will be executed or that the proposed transaction will be completed as contemplated, or at all.
About AI Maverick Intel, Inc.
AI Maverick Intel, Inc. is focused on identifying and developing opportunities at the intersection of artificial intelligence, data platforms, and emerging technology-enabled industries. The Company evaluates strategic acquisitions, partnerships, and scalable platforms designed to drive long-term shareholder value.
About HEAL Access Canada Inc.
HEAL Access Canada Inc., a subsidiary of HEAL Group Holdings Inc., operates an AI-powered health intelligence platform that connects patients, clinicians, and healthcare organizations through a unified, data-driven ecosystem. The platform delivers personalized care pathways, intelligent case management, and continuous patient engagement across multiple dimensions of health and wellness.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements relating to the proposed acquisition of HEAL Access Canada Inc., the anticipated benefits of the transaction, the execution of a definitive agreement, and the future growth, scalability, and commercial potential of the HEAL Access platform. Forward-looking statements are based on current expectations, estimates, and assumptions that involve risks and uncertainties which could cause actual results to differ materially from those expressed or implied. Forward-looking statements may be identified by words such as “may,” “will,” “intends,” “expects,” “believes,” “anticipates,” “plans,” “potential,” and similar expressions.
These risks include, but are not limited to: the ability of the parties to negotiate and execute a definitive agreement; the satisfaction of closing conditions, including regulatory and shareholder approvals; the successful integration of the platform; reliance on information provided by third parties; and general economic and market conditions.
Readers are cautioned not to place undue reliance on forward-looking statements. AIMV undertakes no obligation to update or revise such statements except as required by applicable law.
Contact:
Wayne Cockburn
Chief Executive Officer
AI Maverick Intel, Inc.
(905) 505-0770
aimaverickintel@gmail.com
SOURCE: AI Maverick Intel, Inc.
View the original press release on ACCESS Newswire
Media gallery
